Record-breaking: 7mn 사설 바카라, bn Profit, 11% Margin
Envlo, Nabota, Fexuclue Drive Growth, Aiming for ‘One Product, One Billion’ Vision
Daewoong Pharmaceutical, led by CEO Chang-Jae Lee and Seng-Ho Jeon, disclosed on February 5th its outstanding financial performance for the past year, reporting separate basis 사설 바카라 of 7 million, operating profit of 0 million, and an operating profit margin of 11%. This achievement represents the company's highest performance since its establishment.
The impressive results were attributed to the sustained growth of South Korean innovative drugs, including 'Fexuclue' and 'Envlo,' in the specialized prescription drug (ETC) market. Additionally, the global success of the botulinum toxin 'Nabota' played a pivotal role in this success. Specialized prescription drugs, with a focus on Fexuclue, contributed to 사설 바카라 reaching 5 million, with Fexuclue achieving cumulative 사설 바카라 of approximately million. Fexuclue is actively preparing for global expansion by undergoing new drug applications (NDA) and technology exports (L/O) in 24 countries.
Envlo, a South Korean unique SGLT-2 inhibitor, demonstrated remarkable market penetration, earning its place in major general hospitals. Within six months of its launch, Envlo expanded its product line with the introduction of the metformin combination drug 'Envlomet.' The company accelerated global expansion by securing export contracts for Russia and the Commonwealth of Independent States (CIS). Established prescription drugs such as Ursa, Erdos, Crezet, and Stavic also experienced steady growth, supported by Daewoong Pharmaceutical's distinctive four-stage verification 사설 바카라 strategy.
Nabota, a flagship product, achieved 사설 바카라 of 0 million, with approximately 80% generated through exports. Nabota's presence expanded beyond the UK, Germany, and Austria, entering the Italian market and consistently broadening its European market footprint.
In the global "beauty" market, Nabota demonstrated steady 사설 바카라 growth and is actively preparing for entry into the "therapeutic" market. Partnering with global therapeutic indications firm AEON Biopharma, Inc., Nabota is undergoing clinical trials for conditions such as spasticity, chronic migraine, cervical dystonia, gastroparesis, and Post Traumatic Stress Disorder (PTSD).
To support the sustained growth of Nabota's international 사설 바카라 and expansion into therapeutic indications, Daewoong Pharmaceutical initiated the construction of the Nabota 3 factory last year. Upon completion, the company anticipates a 260% increase in Daewoong Pharmaceutical's annual Nabota production, reaching 13 million vials, compared to the current capacity.
Looking ahead, Daewoong Pharmaceutical plans to continue its preparations for the future alongside recent 사설 바카라 achievements. In the previous year, the company successfully secured technological exports totaling approximately billion. Notably, in January 2023, a significant milestone was reached with a 0 million technology export contract for the fibrosis new drug candidate 'Bersiporocin (DWN-2088)' with China's CS Pharmaceuticals. Following this, in February, a technology export contract for 'Envlo' worth .3 million in Central and South America was signed with the Brazilian pharmaceutical company Moksha8.